. The fact that these peripheral autoreactive B cells are positively selected by self antigens seems paradoxical to B cell tolerance, but raises the possibility that autoantibodies may in some cases perform useful functions (5) . In humans, the origin of natural antibodies and the autoantigens that they recognize remain to be characterized. In this issue of the JCI, Merbl et al. (6) , using an antigen microarray, identified specific autoantigens recognized by natural IgM and, to a lesser extent, IgA antibodies produced during human fetal and neonatal life (6) . In addition, they found that autoantigens recognized by serum IgMs from newborns were remarkably similar among individuals, suggesting that in the absence of xenoantigens, specific autoantigens may select and stimulate autoreactive B cells to produce self-reactive natural IgM antibodies in fetuses (6) . In contrast, IgM and IgA antibodies from mothers showed an antigenic recognition pattern different from that of their newborns. Furthermore, IgM and IgA recognition patterns were extremely diverse among the mothers studied, reflecting the distinct immunological histories of each individual. However, encounters with some common pathogens, such as Gram-negative bacteria, stimulated the production of anti-LPS antibodies in all mothers (6) .
Potential origins of common natural antibody reactivity at birth
What might account for the recognition of the same autoantigens by different individuals during early human development? Antibodies are generated by random recombination of Ig variable (V), diversity (D), and joining (J) gene segments during early B cell development. Analysis of B cells from fetuses and neonates showed that this was not the case in early life (7, 8) .
Rather, Ig gene segment usage in early life is biased toward specific genes, thereby lim-iting the extent of Ig diversity ( Figure 1 ). For example, fetal liver B cells have been shown to have a recombination bias toward heavy chain (H) V H 6-1 and D7-27 segments located at the 3′ end of the V H and D loci ( Figure 1 ) (7, 8) . J H gene usage is also skewed toward more upstream J H 1-4 genes, and J H 6 is rarely found in rearrangements from fetal and neonatal B cells ( Figure 1 ) (7, 8) . Ig diversity in early life is further limited by low activity of terminal deoxynucleotidyl transferase (TDT), an enzyme that adds nontemplate nucleotides between V H -D and D-J H joining regions (7, 8) .
As a consequence of the lack of insertion of nontemplate nucleotides combined with the fact that D7-27, the segment preferentially used in fetal liver B cells, is the shortest D segment, Ig heavy chain (IgH) complementarity-determining region 3 (CDR3) involved in antigen recognition is particularly short in fetuses and neonates compared with that in adults (7, 8) . Taken together, these restrictions to V(D)J recombination that occur during fetal and neonatal life may explain both the generation of B cell clones that recognize common autoantigens and the similarities in antibody repertoires among different individuals. It is likely that this incomplete fetal/neonatal antibody repertoire is not detrimental to neonates, because protective maternal IgG antibodies cross the placenta and provide potent and properly selected antibodies required for host defense.
B cell tolerance checkpoints in fetuses and neonates
IgH CDR3s generated by V(D)J recombination play an essential role in conferring polyreactivity to natural antibodies (3). In adults, higher TDT activity and usage of J H 6 (the longest of all J H s) are responsible for the production of longer IgH CDR3s than those in fetuses/neonates. In addition, TDTdependent nontemplate nucleotides often encode positively charged amino acids rarely found in D segments, which, when combined with long IgH CDR3s, often lead to the production of autoreactive antibodies (1, 7) . Although this random V(D)J recombination described in healthy adults generates a large number of autoreactive B cells, such autoreactive clones are counterselected at two major checkpoints (1, 9) . Central B cell tolerance is established in the bone marrow at the first checkpoint between the early immature and immature B cell stages, and this silences most polyreactive and anti-nuclear antibody-expressing B cells. A second counterselection step mediates the peripheral B cell tolerance checkpoint and serves to remove autoreactive B cells that recently emigrated from the bone marrow before they enter the long-lived mature naive B cell pool (1, 9) . The regulation of central B cell tolerance requires proper B cell receptor (BCR) signaling. Alterations in BCR signaling described in patients with X-linked agammaglobulinemia (XLA) result in a defective central B cell tolerance checkpoint, which is manifested by a failure to counterselect polyreactive developing B cells in these patients (10) . Little is known about the molecules and pathways that regulate human peripheral B cell tolerance checkpoints. Our recent studies sug- reactive clones (6) . Among the neonatal specificities are those encoded by the V H 6-1 gene, which is often used during fetal life and has been reported to intrinsically encode anti-single-stranded DNA and anticardiolipin autoreactive antibodies (11) . How do such autoreactive clones escape B cell tolerance? Perhaps central and peripheral B cell tolerance checkpoints identified in adults do not yet function during fetal liver or fetal bone marrow B cell development. Differences in the thresholds of BCR signaling may provide a basis for differences in central B cell tolerance checkpoint regulation between fetuses/neonates and adults and could thereby lead to increased production of polyreactive B cells. In addition, the immature fetal/neonatal immune system may lack the necessary "mature" T cell population that regulates the peripheral B cell tolerance checkpoint, allowing autoreactive/polyreactive B cells to be recruited in the periphery and secrete natural IgM polyreactive antibodies. Thus, both the mechanisms that generate diversity and those that mediate central and peripheral counterselection in the fetal immune system result in a repertoire of limited diversity and pathogenicity.
Natural antibodies, polyreactive B cells, and autoimmunity Natural antibodies are believed to have beneficial functions. They have been shown to be an essential first line of defense against pathogens through either activation of complement or formation of immune complexes that are delivered to follicular dendritic cells in secondary lymphoid organs (reviewed in ref. 12). Natural antibodies also participate in the clearance of apoptotic cells and thereby limit circulation of autoantigens and reduce the risk of autoimmunity. By extension, autoreactive antibodies encoded by the conserved V H 6-1 gene may help eliminate fetal apoptotic cells and debris containing DNA molecules because those antibodies have anti-nucleic acid reactivity (11) . Later in life, autoreactive V H 6-1-expressing B cells are rare, but autoreactive clones expressing another intrinsically self-reactive V H , V H 4-34, develop and accumulate in the mature naive B cell compartment. B cells expressing antibodies encoded by V H 4-34 variable regions recognize I/i carbohydrate self determinants displayed on red blood cells, and such autoantibodies may participate in the clearance of dying erythrocytes (13). Germlineencoded V H 4-34 antibodies also cross-react with bacterial LPS, suggesting a role in host defense. Despite a potential protective role, the V H 4-34 gene encodes all pathogenic anti-I/i cold-agglutinin antibodies, indicating that natural antibodies can have damaging effects (13) . Indeed, serum natural IgM anti-nonmuscle myosin heavy chain type II (anti-NMHC-II) antibodies have recently been shown to mediate local reperfusion injury after ischemia associated with myocardial infarction, stroke, or surgery (14) . Intracytoplasmic NMHC-II molecules are expressed at the cell surface as a result of hypoxic stress, and binding of natural IgM antibodies that recognize these newly exposed self antigens induces complement activation and tissue damage (14) .
Whether the limited and selective autoimmunity, termed the immunculus, is protective or whether it represents the substrate on which pathogenic autoantibodies develop will depend upon the effectiveness of checkpoints following birth. Patients with SLE and rheumatoid arthritis display defective central and peripheral B cell tolerance checkpoints that lead to the accumulation of a large number of autoreactive/polyreactive B cells in the mature naive B cell compartment (9) . The alteration of these autoreactive/polyreactive B cells through somatic hypermutation and isotype switching may yield clones expressing high-affinity pathogenic autoantibodies. In mice, nucleotide changes in the Ig sequence of an antibody against phosphorylcholine, the dominant hapten on the pneumococcal cell wall, gave rise to antibodies cross-reacting with DNA (15) . In healthy adults, V H 4-34-expressing autoreactive B cells are excluded from germinal centers and the memory B cell compartment (16). However, in SLE patients, V H 4-34-expressing B cells are recruited in germinal centers, where they may produce pathogenic autoantibodies (16) . Indeed, such serum V H 4-34 antibody levels correlate with lupus disease activity (17) .
The events that drive breaks in B cell tolerance are unknown, but evidence is emerging that TLRs contribute to activation of autoreactive/polyreactive B cells. TLRs recognize microbial components as well as endogenous self antigens such as DNA and RNA (18) . Nuclear autoantigens containing DNA and RNA molecules found in the serum of SLE patients may concomitantly trigger autoreactive/polyreactive BCRs and TLRs and thereby induce the production of autoantibodies binding double-stranded DNA and/or histones as well as nuclear ribonucleoproteins in these patients (19) . The role of TLRs during fetal/neonatal B cell ontogeny is unknown. We speculate that TLR binding by self antigens released during developmental apoptosis contributes to activation of polyreactive B cells and secretion of natural antibodies in early human life.
In conclusion, fetal/neonatal autoantibodies are different from adult autoantibodies, especially those associated with autoimmune disease and organ damage. Fetal autoantibodies are IgMs with germline-encoded CDR3s that arise from restricted V(D)J recombination, whereas pathogenic autoantibodies in adults are mostly high-affinity, somatically mutated IgGs that may result from failures of counterselection processes against specific autoantigens. For these reasons, we believe that the immunculus is protective and that defects in the maturation of the immune system later in life lead to abnormal B cell tolerance checkpoints and predispose the individual to autoimmunity.
